AwesomeCapital

Monday, September 30, 2019

Genentech to present positive Tecentriq data

›
Genentech ( OTCQX:RHHBY ) is presenting positive results from the Phase III IMvigor130 study evaluating Tecentriq (atezolizumab) today at t...

Aquestive completes early-stage AQST-108 trial

›
Aquestive Therapeutics (NASDAQ: AQST ) has  completed  its Phase 1 dose escalation proof-of-concept study in healthy subjects for AQST-108....

Moderna announces open IND for Propionic Acidemia program

›
The FDA has  completed  the review of Moderna’s (NASDAQ: MRNA ) IND application for mRNA-3927, its investigational mRNA therapeutic for pro...

Endo International rises 2.2% after litigation matters resolved

›
Endo International (NASDAQ: ENDP )  gains 2.2%  in premarket trading after the culmination of  two litigation matters  regarding the compou...

Mallinckrodt +13% after settling Ohio opioid cases

›
Mallinckrodt (NYSE: MNK ) races higher in early trading after  settling  a legal case with two counties in Ohio involving opioid usage. T...

FDA OKs Turning Point’s IND for TPX-0046

›
The FDA  clears  Turning Point Therapeutics’ (NASDAQ: TPTX ) IND for TPX-0046, a novel therapy targeting solid tumors with abnormal RET gen...

Acasti Pharma updates on Trilogy 1 and 2 trials

›
Acasti Pharma (NASDAQ: ACST )  reports  additional milestones reached and provides a business update on its clinical trials. ACST’s TRILO...
‹
›
Home
View web version
Powered by Blogger.